Radiation oncology firm Accuray has received the CE Mark for its Radixact treatment delivery platform.
The package includes Accuray's Precision treatment planning system and its iDMS data management system. The platform increases the treatment speed and ease of use of Accuray's TomoTherapy device, the company said.
Radixact received clearance from the U.S. Food and Drug Administration (FDA) in June, according to the firm.
